Scribe Therapeutics Starts IPO Effort For CRISPR Pipeline Development (SCTX)
· seekingalpha.com
Scribe Therapeutics is a Phase 1 clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, targeting atherosclerotic cardiovascular disease. Read the more here.
Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs.He also leads the investing group IPO E...